BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 1720273)

  • 1. [Chemotherapy of prostatic cancer].
    Hirao Y; Kubota K; Yoshie T; Tabata S; Samma S; Ozono S; Okajima E; Sasaki K; Yoshikawa M; Tsumatani K
    Hinyokika Kiyo; 1991 Aug; 37(8):817-24. PubMed ID: 1720273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment for hormone-refractory or relapsing prostatic cancer].
    Hirao Y; Ozono S; Okajima E
    Gan To Kagaku Ryoho; 1996 Mar; 23(4):418-26. PubMed ID: 8678492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Response to chemotherapy in endocrine therapy-relapsed and -resistant prostate cancer].
    Akimoto S; Akakura K; Masai M; Shimazaki J
    Hinyokika Kiyo; 1991 Jan; 37(1):31-7. PubMed ID: 1707216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Neoadjuvant chemoradiotherapy in locally invasive transitional cell carcinoma of the urinary bladder: early results of PVB and CAP therapy].
    Momose H; Arai K; Nakagawa Y; Fujimoto K; Tsujimoto S; Cho M; Tani Y; Saka M; Nakatsuji F; Iwai A
    Hinyokika Kiyo; 1989 May; 35(5):781-8. PubMed ID: 2478001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cyclophosphamide, adriamycin and cisplatinum combination chemotherapy for advanced urothelial and prostatic carcinoma].
    Tsukamoto T; Tanoguchi H; Nakazono M; Murai M; Tachibana M; Deguchi N; Baba S; Hata M; Jitsukawa S; Tazaki H
    Gan To Kagaku Ryoho; 1987 Dec; 14(12):3259-64. PubMed ID: 3688891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Combination chemotherapy with ifosfamide (or cyclophosphamide), adriamycin, cis-platinum and peplomycin (IAPP) for hormonally resistant metastatic prostatic cancer].
    Maeda O; Saiki S; Kinouchi T; Kuroda M; Miki T; Usami M; Kotake T
    Hinyokika Kiyo; 1991 Dec; 37(12):1657-62. PubMed ID: 1723841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical evaluation of chemotherapy in urologic cancer].
    Miki T; Kuroda M; Kotake T
    Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1349-57. PubMed ID: 2471457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Induction therapy with CDDP and ADM for stage D prostatic cancer and its clinical response].
    Yushita Y; Sakai H; Nomata K; Suzu H; Minami Y; Ogawa S; Yamashita S; Kanetake H; Saito Y
    Hinyokika Kiyo; 1990 Dec; 36(12):1415-21. PubMed ID: 2075879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Evaluation of efficacy of treatment for 30 children with neuroblastoma].
    Sun XF; Liu DG; Su YS; Lin TY; Chen XQ; He YJ
    Ai Zheng; 2003 Dec; 22(12):1343-5. PubMed ID: 14693065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
    Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E
    Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paclitaxel/carboplatin versus cyclophosphamide/adriamycin/cisplatin as postoperative adjuvant chemotherapy for advanced endometrial adenocarcinoma.
    Hidaka T; Nakamura T; Shima T; Yuki H; Saito S
    J Obstet Gynaecol Res; 2006 Jun; 32(3):330-7. PubMed ID: 16764625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Neoadjuvant and adjuvant chemotherapy of bladder cancer].
    Kuroda M; Kotake T
    Gan To Kagaku Ryoho; 1994 Oct; 21 Suppl 3():362-9. PubMed ID: 7986116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Sequential combination chemotherapy consisting of vincristine, peplomycin, methotrexate, cis-diamminedichloroplatinum (II) and adriamycin in urothelial cancer].
    Konami T; Wakabayashi Y; Kim T; Ishida A; Arai Y; Konishi T; Pak K; Takeuchi H; Tomoyoshi T; Watanabe J
    Hinyokika Kiyo; 1989 Feb; 35(2):231-7. PubMed ID: 2472048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment results of combined hormone and chemotherapy in patients with advanced prostate cancer].
    Uekado Y
    Hinyokika Kiyo; 1991 Aug; 37(8):825-31. PubMed ID: 1957724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the G.O.I.M. (Gruppo Oncologico Italia Meridionale).
    Gebbia V; Galetta D; Lorusso V; Caruso M; Verderame F; Pezzella G; Borsellino N; Durini E; Valenza R; Agostara B; Colucci G;
    Lung Cancer; 2008 Sep; 61(3):369-77. PubMed ID: 18308419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term survival in advanced ovarian cancer after cytoreduction and chemotherapy treatment.
    Del Campo JM; Felip E; Rubio D; Vidal R; Bermejo B; Colomer R; Zanon V
    Gynecol Oncol; 1994 Apr; 53(1):27-32. PubMed ID: 8175018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cisplatin containing combination chemotherapy of advanced germ cell line testicular tumours.
    Bodrogi I; Baki M; Horti J; Géczi L; Liszka G; Ottó S; Hindy I; Eckhardt S; Sugár J
    Acta Med Hung; 1994; 50(3-4):275-92. PubMed ID: 8587840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroblastoma.
    Meir HM; Balawi I; Nayel H; Yousef MK; Badawood S; Al-Mobarak M
    Saudi Med J; 2001 Aug; 22(8):674-80. PubMed ID: 11573111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Chemotherapy of carcinoma of the prostate and testis: experimental study in vivo and in vitro].
    Okada K; Kanamaru H; Yoshiki T; Hashimura T; Nishimura K; Hida S; Nishio Y; Oishi K; Yoshida O; Yamauchi T
    Hinyokika Kiyo; 1988 Nov; 34(11):1911-6. PubMed ID: 2468265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.